Abstract Rationale Metabolic dysfunction-associated fatty liver disease (MAFLD) is a systemic inflammatory condition with possible pulmonary sequelae, but its effect on outcomes in patients hospitalized for interstitial lung disease (ILD) flares is unknown. Methods We analyzed the 2017-2022 National Inpatient Sample (NIS) in a cross-sectional study. Adult hospitalizations with ILD flare were identified with validated codes. MAFLD was determined based on ICD-10 codes. Survey-weighted analyses accounted for complex sampling. Baseline characteristics were compared by MAFLD status. Multivariable logistic and linear regressions, adjusted for demographics, comorbidities, and hospital factors, modeled the association of MAFLD with inpatient mortality, mechanical ventilation, composite adverse outcome (death or ventilation), log-transformed length of stay (LOS), and total charges. Adjusted marginal effects and predictive probabilities were estimated. Results Of ∼121,000 weighted ILD flare hospitalizations, 2.8 % had concomitant MAFLD.Compared to patients without MAFLD, affected individuals were younger (66 vs 69 years), had a higher burden of comorbidities (Charlson ≥ 3: 68 % vs 36 %), and were more likely to have public insurance. Outcomes after multivariable adjustment are stated in Table 1 as attached in image. Conclusions MAFLD was independently associated with increased inpatient mortality and higher utilization of health care resources among patients hospitalized with ILD flares. These data support MAFLD as a clinically significant systemic modifier of ILD, that warrants prospective evaluation of metabolic-inflammatory pathophysiology and treatment approaches. This abstract is funded by: None
Lim et al. (Fri,) studied this question.